Business & Finance
Zealand Pharma widens loss in 2017 full-year
8 March 2018 -

Biotechnology company Zealand Pharma A/S (CPH:ZEAL) on Wednesday reported net loss of DKK272.3m, or DKK9.77 per diluted share, for the 12-month period, from 1 January 2017 to 31 December 2017.

This was a 77% decline over net loss of DKK153.9m, or DKK6.33 per diluted share, in 2016.

Revenues for the year were DKK139.8m, down by 40% as compared with DKK234.8m in 2016.

Royalty revenues for the year were DKK38.8m, up by 59% as compared with 2016, while milestone revenues were DKK101.0m, down by 52% as compared with 2016.

Reportedly, these full year results were in line with guidance.